Liver transplantation for Budd-Chiari syndrome--palliation or cure?

This report documents two cases of Budd-Chiari syndrome (BCS) with essential thrombocytosis and antithrombin (AT) III deficiency as underlying etiological factors. Orthotopic liver transplantation was successfully performed in both patients but with different therapeutic intention. In the patient with essential thrombocytosis, hepatic transplantation only relieved the symptoms of the predisposing thrombogenic condition; it did not cure the underlying disorder. Prophylactic long-term anticoagulation, as well as adjuvant therapy for the causative disease, remained necessary. On the other hand, in the patient with AT III deficiency, liver transplantation was curative, resulting in complete reconstitution of serum AT III activity with resolution of the hypercoagulable state postoperatively. Thus, depending on the underlying etiology, liver transplantation for BCS can be considered as palliative, necessitating long-term adjuvant therapy, or as curative, with correction of a metabolic defect.
AuthorsH Lang, K J Oldhafer, E Kupsch, B Ringe, R Pichlmayr
JournalTransplant international : official journal of the European Society for Organ Transplantation (Transpl Int) Vol. 7 Issue 2 Pg. 115-9 ( 1994) ISSN: 0934-0874 [Print] GERMANY
PMID7513998 (Publication Type: Case Reports, Journal Article)
  • Adult
  • Antithrombin III Deficiency
  • Budd-Chiari Syndrome (complications, pathology, therapy)
  • Child
  • Female
  • Humans
  • Liver Transplantation
  • Male
  • Palliative Care
  • Thrombocythemia, Essential (complications, pathology, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: